Abstract
An in vitro assay, which evaluates drug effect on 3H-thymidine incorporation, was used to investigate the absolute and relative activities of cisplatin (DDP), carboplatin (CBDCA) and iproplatin (CHIP) on 317 specimens from untreated tumors, including breast and ovarian cancers and malignant melanomas. Similar activities were generally observed for DDP and CHIP, whereas CBDCA exhibited a lower, although not significantly different cytotoxicity on breast and ovarian cancers. The relative activities of Platinum analogues were analyzed on 239 two-way drug sensitivity comparisons. The overall agreement rates ranged from 80.2 to 83.9% for the different comparisons. High coresistance, from 61.1 to 93.8%, was observed for all the comparisons, regardless of the tumor type. Cosensitivity rates were poor for breast and ovarian cancers, from 0 to 37.5%, whereas for melanomas an association in sensitivity was observed in 80% of the cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cleare MJ, Hydes PC, Malerbi BW, Watkins DM: Antitumor platinum complexes: relationships between chemical properties and activity. Biochimie 60:835–850, 1978
Wilkinson R, Cox PJ, Jones M, Harrap KR: Selection of potential second generation platinum compounds. Biochemie 60:851–857, 1978
Rose WC, Schurig JE: Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 12 (suppl A): 1–19, 1985
Wiltshaw E: Ovarian trials at the Royal Marsden. Cancer Treat Rev 12 (Suppl A):67–72, 1985
Ozols RF, Behrens BC, Ostchega Y, Young RC: High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 12 (Suppl A):59–66, 1985
Smith IR, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Colvert AH, Yarnold J, Gless JP, Baker J, Ford HT: Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 69:43–46, 1985
Hornedo-Muguiro J, So M, Spaulding MB, Van Echo DA, Danchover R, Ettinger D, Aisner J: Phase II trial of carboplatin (CBDCA) in aerodigestive malignancies. (Abstr) Proc Am Soc Clin Oncol 4:136, 1985
Muggia FM, Lira-Puerto V, Carugati A, Pavlovsky S: Potentials for platinum analogs in the treatment of cancer of the uterine cervix. Cancer Treat Rev 12 (Suppl A):93–100, 1985
Peckham MJ, Horwich A, Brada M, Drury A, Hendry WF: Cisdiammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumors: a preliminary report. Cancer Treat Rev 12 (Suppl A):101–110, 1985
Canetta R, Rozencweig M, Carter SK: Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12 (Suppl A):125–136, 1985
Boven E, van der Vijgh WJF, Nanta NM, Schluper HMM, Pinedo HM: Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 45:86–90, 1985
Drewinko B, Yang LY, Trujillo JM: Comparative cytotoxicity between cisplatin and second generation platinum analogues. Invest New Drugs 3:335–340, 1985
Bramwell VHC, Crowther D, O'Malley S, Swindell R, Johnson R, Cooper EH, Thatcher N, Howell A: Activity of JM9 in advanced ovarian cancer: a phase I–II trial. Cancer Treat Rep 69:409–416, 1985
Sanfilippo O, Daidone MG, Costa A, Canetta R, Silvestrini R: Estimation of differential in vitro sensitivity of non-Hodgkin Lymphomas to anticancer drugs. Europ J Cancer 17:217–226, 1981
Daidone MG, Silvestrini R, Sanfilippo O, Zaffaroni N, Varini M, De Lena M: Reliability of an in vitro short-term assay to predict the drug sensitivity of human breast cancer. Cancer 56:450–456, 1985
Sanfilippo O, Silvestrini R, Zaffaroni N, Piva L, Pizzocaro G: Application of an in vitro antimetabolic assay to human germ cell testicular tumors for the preclinical evaluation of drug sensitivity. Cancer 58:1441–1447, 1986
Daidone MG, Silvestrini R: Modelli sperimentali in vitro per lo studio della chemiosensibilità dei tumori ovarici. Neoplasie Ginecologiche. Candiani GB, Veronesi U, Di Re F, Santoro A eds. Casa Editrice Ambrosiana. in press.
Silvestrini R, Sanfilippo O, Daidone MG: An attempt to use incorporation of radioactive nucleic acid precursor to predict clinical response. In: Dendy PP, Hill BT (eds) Human Tumor Drug Sensitivity Testing in Vitro — Techniques and Clinical Applications. Academic Press, New York, 1983, pp 281–290
Sanfilippo O, Daidone MG, Zaffaroni N, Silvestrini R: Development of a nucleotide precursor incorporation assay for testing drug sensitivity of human tumors. In: Hofmann V, Martz G (eds) Predictive Drug Testing on Human Tumors Cells. Springer-Verlag, Berlin, 1984, pp 127–139
Silvestrini R, Sanfilippo O, Daidone MG, Zaffaroni N: Predictive relevance for clinical outcome of in vitro sensitivity evaluated through antimetabolic assay. In: Hofmann V, Martz G (eds) Predictive Drug Testing on Human Tumors Cells. Springer-Verlag, Berlin, 1984, pp 140–150
Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 58:1982–1988, 1985
Daidone MG, Silvestrini R, Zaffaroni N, De Marco C: Reliability of a short-term antimetabolic assay in testing drug sensitivity of ovarian cancers. In: Proceedings of the 13th Congress of Chemotherapy, Vienna, 1983, pp 483–484
Costa A, Piazza R, Sanfilippo O, Silvestrini R: A quantitative test for chemosensitivity of short-term cultures of human lymphomas. Tumori 63:237–247, 1977
Tisman G, Herbert V, Edlis H: Determination of therapeutic index of drugs by in vitro sensitivity tests using human host and tumor cell suspensions. Cancer Chemother Rep 57:11–19, 1973
Tew KD, Taylor DM: The relationship of thymidine metabolism to the use of fractional incorporation as a measure of DNA synthesis and tissue proliferation. Eur J Cancer 14:153–168, 1978
Ostrow S, Egorin M, Aisner J, Bachur N, Wiernik PH: High dose cis-diamminedichloroplatinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials 3:23–28, 1980
Prestayko AW: Cisplatin and analogues: a new class of anticancer drugs. In: Crooke ST, Preastayko AW (eds) Cancer and Chemotherapy. Academic Press, New York, 1981, pp 133–154
Chary KK, Higby DJ, Handerson ES: Phase I study of high dose Cis-dichlorodiammineplatinum (II) with forced diuresis. Cancer Treat Rep 61:367–370, 1977
Hrubisko M, Balazova E, Ujhazy V: Drug resistance, induction and cross-resistance studies with Pt-complexes. Neoplasma, 31:649–652, 1984
Aparicio LA, Rozencweig M, Mattelaer M, Delforge A, Sanders C, Rombout W, Tagnon H, Stryckmans P, Kenis Y, Klastersky J: Comparative effect of cisplatin (DDP), TNO-6, Carboplatin (CBDCA), CHIP and JM40 in human myeloid and human tumor clonogenic assays. (Abstract) Proc Amer Assoc Cancer Res 24:1155, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Daidone, M.G., Silvestrini, R., Zaffaroni, N. et al. Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay. Invest New Drugs 5, 245–250 (1987). https://doi.org/10.1007/BF00175294
Issue Date:
DOI: https://doi.org/10.1007/BF00175294